Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 5209-5218, October 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Prewett, M.
Right arrow Articles by Hicklin, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prewett, M.
Right arrow Articles by Hicklin, D. J.
[Cancer Research 59, 5209-5218, October 15, 1999]
© 1999 American Association for Cancer Research

Experimental Therapeutics

Antivascular Endothelial Growth Factor Receptor (Fetal Liver Kinase 1) Monoclonal Antibody Inhibits Tumor Angiogenesis and Growth of Several Mouse and Human Tumors

Marie Prewett, James Huber, Yiwen Li, Angel Santiago, William O’Connor, Karen King, Jay Overholser, Andrea Hooper, Bronislaw Pytowski, Larry Witte, Peter Bohlen and Daniel J. Hicklin1

Departments of Immunology [M. P., J. H., Y. L., W. O., K. K., J. O., A. H., D. J. H.], Molecular and Cell Biology [A. S., B. P., L. W.], and Research [P. B.], ImClone Systems Inc., New York, New York 10014

Tumor angiogenesis is mediated by tumor-secreted angiogenic growth factors that interact with their surface receptors expressed on endothelial cells. Vascular endothelial growth factor (VEGF) and its receptor [fetal liver kinase 1 (Flk-1)/kinase insert domain-containing receptor] play an important role in vascular permeability and tumor angiogenesis. Previously, we reported on the development of anti-Flk-1 and antikinase insert domain-containing receptor monoclonal antibodies (mAbs) that potently inhibit VEGF binding and receptor signaling. Here, we report the effect of anti-Flk-1 mAb (DC101) on angiogenesis and tumor growth. Angiogenesis in vivo was examined using a growth factor supplemented (basic fibroblast growth factor + VEGF) Matrigel plug and an alginate-encapsulated tumor cell (Lewis lung) assay in C57BL/6 mice. Systemic administration of DC101 every 3 days markedly reduced neovascularization of Matrigel plugs and tumor-containing alginate beads in a dose-dependent fashion. Histological analysis of Matrigel plugs showed reduced numbers of endothelial cells and vessel structures. Several mouse tumors and human tumor xenografts in athymic mice were used to examine the effect of anti-Flk-1 mAb treatment on tumor angiogenesis and growth. Anti-Flk-1 mAb treatment significantly suppressed the growth of primary murine Lewis lung, 4T1 mammary, and B16 melanoma tumors and growth of Lewis lung metastases. DC101 also completely inhibited the growth of established epidermoid, glioblastoma, pancreatic, and renal human tumor xenografts. Histological examination of anti-Flk-1 mAb-treated tumors showed evidence of decreased microvessel density, tumor cell apoptosis, decreased tumor cell proliferation, and extensive tumor necrosis. These findings support the conclusion that anti-Flk-1 mAb treatment inhibits tumor growth by suppression of tumor-induced neovascularization and demonstrate the potential for therapeutic application of anti-VEGF receptor antibody in the treatment of angiogenesis-dependent tumors.




This article has been cited by other articles:


Home page
 JNMHome page
W. Cai and X. Chen
Multimodality Molecular Imaging of Tumor Angiogenesis
J. Nucl. Med., June 1, 2008; 49(Suppl_2): 113S - 128S.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
W. Yan, B. Bentley, and R. Shao
Distinct Angiogenic Mediators Are Required for Basic Fibroblast Growth Factor- and Vascular Endothelial Growth Factor-induced Angiogenesis: The Role of Cytoplasmic Tyrosine Kinase c-Abl in Tumor Angiogenesis
Mol. Biol. Cell, May 1, 2008; 19(5): 2278 - 2288.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Korsisaari, J. Ross, X. Wu, M. Kowanetz, N. Pal, L. Hall, J. Eastham-Anderson, W. F. Forrest, N. Van Bruggen, F. V. Peale, et al.
Blocking Vascular Endothelial Growth Factor-A Inhibits the Growth of Pituitary Adenomas and Lowers Serum Prolactin Level in a Mouse Model of Multiple Endocrine Neoplasia Type 1
Clin. Cancer Res., January 1, 2008; 14(1): 249 - 258.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
H. Mochimaru, N. Nagai, G. Hasegawa, C. Kudo-Saito, T. Yaguchi, Y. Usui, T. Kurihara, T. Koto, S. Satofuka, H. Shinoda, et al.
Suppression of Choroidal Neovascularization by Dendritic Cell Vaccination Targeting VEGFR2
Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4795 - 4801.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
D. Belloni, S. Scabini, C. Foglieni, L. Veschini, A. Giazzon, B. Colombo, A. Fulgenzi, K. B. Helle, M. E. Ferrero, A. Corti, et al.
The vasostatin-I fragment of chromogranin A inhibits VEGF-induced endothelial cell proliferation and migration
FASEB J, October 1, 2007; 21(12): 3052 - 3062.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Youssoufian, D. J. Hicklin, and E. K. Rowinsky
Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy
Clin. Cancer Res., September 15, 2007; 13(18): 5544s - 5548s.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Huang, X. Chen, M. M. Dikov, S. V. Novitskiy, C. A. Mosse, L. Yang, and D. P. Carbone
Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF
Blood, July 15, 2007; 110(2): 624 - 631.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. L. Reidy, K. Y. Chung, J. P. Timoney, V. J. Park, E. Hollywood, N. T. Sklarin, R. J. Muller, and L. B. Saltz
Bevacizumab 5 mg/kg Can Be Infused Safely Over 10 Minutes
J. Clin. Oncol., July 1, 2007; 25(19): 2691 - 2695.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. A. Manning, J. G.M. Ullman, J. M. Leatherman, J. M. Asquith, T. R. Hansen, T. D. Armstrong, D. J. Hicklin, E. M. Jaffee, and L. A. Emens
A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism
Clin. Cancer Res., July 1, 2007; 13(13): 3951 - 3959.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
N. Korsisaari, I. M. Kasman, W. F. Forrest, N. Pal, W. Bai, G. Fuh, F. V. Peale, R. Smits, and N. Ferrara
From the Cover: Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice
PNAS, June 19, 2007; 104(25): 10625 - 10630.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
M. Wirzenius, T. Tammela, M. Uutela, Y. He, T. Odorisio, G. Zambruno, J. A. Nagy, H. F. Dvorak, S. Yla-Herttuala, M. Shibuya, et al.
Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting
J. Exp. Med., June 11, 2007; 204(6): 1431 - 1440.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. V. Kozin, F. Winkler, I. Garkavtsev, D. J. Hicklin, R. K. Jain, and Y. Boucher
Human Tumor Xenografts Recurring after Radiotherapy Are More Sensitive to Anti-Vascular Endothelial Growth Factor Receptor-2 Treatment than Treatment-Naive Tumors
Cancer Res., June 1, 2007; 67(11): 5076 - 5082.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Folkins, S. Man, P. Xu, Y. Shaked, D. J. Hicklin, and R. S. Kerbel
Anticancer Therapies Combining Antiangiogenic and Tumor Cell Cytotoxic Effects Reduce the Tumor Stem-Like Cell Fraction in Glioma Xenograft Tumors
Cancer Res., April 15, 2007; 67(8): 3560 - 3564.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
J. Tabernero
The Role of VEGF and EGFR Inhibition: Implications for Combining Anti-VEGF and Anti-EGFR Agents
Mol. Cancer Res., March 1, 2007; 5(3): 203 - 220.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
N. Shraga-Heled, O. Kessler, C. Prahst, J. Kroll, H. Augustin, and G. Neufeld
Neuropilin-1 and neuropilin-2 enhance VEGF121 stimulated signal transduction by the VEGFR-2 receptor
FASEB J, March 1, 2007; 21(3): 915 - 926.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Futamura, H. Kamino, Y. Miyamoto, N. Kitamura, Y. Nakamura, S. Ohnishi, Y. Masuda, and H. Arakawa
Possible Role of Semaphorin 3F, a Candidate Tumor Suppressor Gene at 3p21.3, in p53-Regulated Tumor Angiogenesis Suppression
Cancer Res., February 15, 2007; 67(4): 1451 - 1460.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. Cai, K. Chen, K. A. Mohamedali, Q. Cao, S. S. Gambhir, M. G. Rosenblum, and X. Chen
PET of Vascular Endothelial Growth Factor Receptor Expression
J. Nucl. Med., December 1, 2006; 47(12): 2048 - 2056.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. M. Brantley-Sieders, W. B. Fang, Y. Hwang, D. Hicks, and J. Chen
Ephrin-A1 Facilitates Mammary Tumor Metastasis through an Angiogenesis-Dependent Mechanism Mediated by EphA Receptor and Vascular Endothelial Growth Factor in Mice
Cancer Res., November 1, 2006; 66(21): 10315 - 10324.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
W. Cai, J. Rao, S. S. Gambhir, and X. Chen
How molecular imaging is speeding up antiangiogenic drug development.
Mol. Cancer Ther., November 1, 2006; 5(11): 2624 - 2633.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Ishizaki, T. Tsunoda, S. Wada, M. Yamauchi, M. Shibuya, and H. Tahara
Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1.
Clin. Cancer Res., October 1, 2006; 12(19): 5841 - 5849.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
Y. Shaked, A. Ciarrocchi, M. Franco, C. R. Lee, S. Man, A. M. Cheung, D. J. Hicklin, D. Chaplin, F. S. Foster, R. Benezra, et al.
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.
Science, September 22, 2006; 313(5794): 1785 - 1787.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Troiani, O. Lockerbie, M. Morrow, F. Ciardiello, and S. G. Eckhardt
Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases.
Mol. Cancer Ther., July 1, 2006; 5(7): 1883 - 1894.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Heon Seo, H.-M. Ko, H.-A Kim, J.-H. Choi, S. Jun Park, K.-J. Kim, H.-K. Lee, and S.-Y. Im
Platelet-Activating Factor Induces Up-regulation of Antiapoptotic Factors in a Melanoma Cell Line through Nuclear Factor-{kappa}B Activation.
Cancer Res., May 1, 2006; 66(9): 4681 - 4686.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Franco, S. Man, L. Chen, U. Emmenegger, Y. Shaked, A. M. Cheung, A. S. Brown, D. J. Hicklin, F. S. Foster, and R. S. Kerbel
Targeted Anti-Vascular Endothelial Growth Factor Receptor-2 Therapy Leads to Short-term and Long-term Impairment of Vascular Function and Increase in Tumor Hypoxia.
Cancer Res., April 1, 2006; 66(7): 3639 - 3648.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Luo, Y.-J. Wen, Z.-Y. Ding, C.-H. Fu, Y. Wu, J.-Y. Liu, Q. Li, Q.-M. He, X. Zhao, Y. Jiang, et al.
Immunotherapy of tumors with protein vaccine based on chicken homologous tie-2.
Clin. Cancer Res., March 15, 2006; 12(6): 1813 - 1819.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Fuh, P. Wu, W.-C. Liang, M. Ultsch, C. V. Lee, B. Moffat, and C. Wiesmann
Structure-Function Studies of Two Synthetic Anti-vascular Endothelial Growth Factor Fabs and Comparison with the AvastinTM Fab
J. Biol. Chem., March 10, 2006; 281(10): 6625 - 6631.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Roberts, B. Kloos, M. Cassella, S. Podgrabinska, K. Persaud, Y. Wu, B. Pytowski, and M. Skobe
Inhibition of VEGFR-3 Activation with the Antagonistic Antibody More Potently Suppresses Lymph Node and Distant Metastases than Inactivation of VEGFR-2.
Cancer Res., March 1, 2006; 66(5): 2650 - 2657.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
X. Chang, G. L. Firestone, and L. F. Bjeldanes
Inhibition of growth factor-induced Ras signaling in vascular endothelial cells and angiogenesis by 3,3'-diindolylmethane
Carcinogenesis, March 1, 2006; 27(3): 541 - 550.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
D. Vitolo, L. Ciocci, G. Deriu, S. Spinelli, S. Cortese, L. Masuelli, S. Morrone, M. J. Filice, G. F. Coloni, P. G. Natali, et al.
Laminin {alpha}2 Chain-Positive Vessels and Epidermal Growth Factor in Lung Neuroendocrine Carcinoma: A Model of a Novel Cooperative Role of Laminin-2 and Epidermal Growth Factor in Vessel Neoplastic Invasion and Metastasis
Am. J. Pathol., March 1, 2006; 168(3): 991 - 1003.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Sun, S. Stevanovic, M. Song, A. Schwantes, C. J. Kirkpatrick, D. Schadendorf, and K. Cichutek
The kinase insert domain-containing receptor is an angiogenesis-associated antigen recognized by human cytotoxic T lymphocytes
Blood, February 15, 2006; 107(4): 1476 - 1483.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
R. Zent and A. Pozzi
Antiangiogenic Therapy in Diabetic Nephropathy
J. Am. Soc. Nephrol., February 1, 2006; 17(2): 325 - 327.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
A. J. Garton, A. P.A. Crew, M. Franklin, A. R. Cooke, G. M. Wynne, L. Castaldo, J. Kahler, S. L. Winski, A. Franks, E. N. Brown, et al.
OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models
Cancer Res., January 15, 2006; 66(2): 1015 - 1024.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Kuramochi, K. Hayashi, K. Uchida, S. Miyakura, D. Shimizu, D. Vallbohmer, S. Park, K. D. Danenberg, K. Takasaki, and P. V. Danenberg
Vascular Endothelial Growth Factor Messenger RNA Expression Level Is Preserved in Liver Metastases Compared with Corresponding Primary Colorectal Cancer
Clin. Cancer Res., January 1, 2006; 12(1): 29 - 33.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Sahni, A. A. Khorana, R. B. Baggs, H. Peng, and C. W. Francis
FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis
Blood, January 1, 2006; 107(1): 126 - 131.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
H Yoshiji, S Kuriyama, R Noguchi, J Yoshii, Y Ikenaka, K Yanase, T Namisaki, M Kitade, M Uemura, T Masaki, et al.
Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice
Gut, December 1, 2005; 54(12): 1768 - 1775.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
D. W. Miller, S. Vosseler, N. Mirancea, D. J. Hicklin, P. Bohlen, H. E. Volcker, F. G. Holz, and N. E. Fusenig
Rapid Vessel Regression, Protease Inhibition, and Stromal Normalization upon Short-Term Vascular Endothelial Growth Factor Receptor 2 Inhibition in Skin Carcinoma Heterotransplants
Am. J. Pathol., November 1, 2005; 167(5): 1389 - 1403.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. A. Laheru, D. M. Pardoll, and E. M. Jaffee
Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology
Mol. Cancer Ther., November 1, 2005; 4(11): 1645 - 1652.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. D. D'Andrea, G. Iaccarino, R. Fattorusso, D. Sorriento, C. Carannante, D. Capasso, B. Trimarco, and C. Pedone
Targeting angiogenesis: Structural characterization and biological properties of a de novo engineered VEGF mimicking peptide
PNAS, October 4, 2005; 102(40): 14215 - 14220.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
K. Hamada, T. Sasaki, P. A. Koni, M. Natsui, H. Kishimoto, J. Sasaki, N. Yajima, Y. Horie, G. Hasegawa, M. Naito, et al.
The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis
Genes & Dev., September 1, 2005; 19(17): 2054 - 2065.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Lamagna, K. M. Hodivala-Dilke, B. A. Imhof, and M. Aurrand-Lions
Antibody against Junctional Adhesion Molecule-C Inhibits Angiogenesis and Tumor Growth
Cancer Res., July 1, 2005; 65(13): 5703 - 5710.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Lamszus, M. A. Brockmann, C. Eckerich, P. Bohlen, C. May, U. Mangold, R. Fillbrandt, and M. Westphal
Inhibition of Glioblastoma Angiogenesis and Invasion by Combined Treatments Directed Against Vascular Endothelial Growth Factor Receptor-2, Epidermal Growth Factor Receptor, and Vascular Endothelial-Cadherin
Clin. Cancer Res., July 1, 2005; 11(13): 4934 - 4940.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Wada, T. Tsunoda, T. Baba, F. J. Primus, H. Kuwano, M. Shibuya, and H. Tahara
Rationale for Antiangiogenic Cancer Therapy with Vaccination Using Epitope Peptides Derived from Human Vascular Endothelial Growth Factor Receptor 2
Cancer Res., June 1, 2005; 65(11): 4939 - 4946.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
S. A. McGrath-Morrow, C. Cho, C. Cho, L. Zhen, D. J. Hicklin, and R. M. Tuder
Vascular Endothelial Growth Factor Receptor 2 Blockade Disrupts Postnatal Lung Development
Am. J. Respir. Cell Mol. Biol., May 1, 2005; 32(5): 420 - 427.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
X. Jimenez, D. Lu, L. Brennan, K. Persaud, M. Liu, H. Miao, L. Witte, and Z. Zhu
A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3
Mol. Cancer Ther., March 1, 2005; 4(3): 427 - 434.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. A. Pauli, H. Tang, J. Wang, P. Bohlen, R. Posser, T. Hartman, M. V. Sauer, J. Kitajewski, and R. C. Zimmermann
The Vascular Endothelial Growth Factor (VEGF)/VEGF Receptor 2 Pathway Is Critical for Blood Vessel Survival in Corpora Lutea of Pregnancy in the Rodent
Endocrinology, March 1, 2005; 146(3): 1301 - 1311.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Murga, O. Fernandez-Capetillo, and G. Tosato
Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2
Blood, March 1, 2005; 105(5): 1992 - 1999.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Vosseler, N. Mirancea, P. Bohlen, M. M. Mueller, and N. E. Fusenig
Angiogenesis Inhibition by Vascular Endothelial Growth Factor Receptor-2 Blockade Reduces Stromal Matrix Metalloproteinase Expression, Normalizes Stromal Tissue, and Reverts Epithelial Tumor Phenotype in Surface Heterotransplants
Cancer Res., February 15, 2005; 65(4): 1294 - 1305.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. J. Hicklin and L. M. Ellis
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
J. Clin. Oncol., February 10, 2005; 23(5): 1011 - 1027.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. R. Reynolds, L. E. Reynolds, T. E. Nagel, J. C. Lively, S. D. Robinson, D. J. Hicklin, S. C. Bodary, and K. M. Hodivala-Dilke
Elevated Flk1 (Vascular Endothelial Growth Factor Receptor 2) Signaling Mediates Enhanced Angiogenesis in {beta}3-Integrin-Deficient Mice
Cancer Res., December 1, 2004; 64(23): 8643 - 8650.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
A. Hoeben, B. Landuyt, M. S. Highley, H. Wildiers, A. T. Van Oosterom, and E. A. De Bruijn
Vascular Endothelial Growth Factor and Angiogenesis
Pharmacol. Rev., December 1, 2004; 56(4): 549 - 580.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
S. D. Robinson, L. E. Reynolds, L. Wyder, D. J. Hicklin, and K. M. Hodivala-Dilke
{beta}3-Integrin Regulates Vascular Endothelial Growth Factor-A-Dependent Permeability
Arterioscler. Thromb. Vasc. Biol., November 1, 2004; 24(11): 2108 - 2114.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
C. Sarkar, D. Chakroborty, R. B. Mitra, S. Banerjee, P. S. Dasgupta, and S. Basu
Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells
Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1554 - H1560.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Bocci, S. Man, S. K. Green, G. Francia, J. M. L. Ebos, J. M. du Manoir, A. Weinerman, U. Emmenegger, L. Ma, P. Thorpe, et al.
Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies
Cancer Res., September 15, 2004; 64(18): 6616 - 6625.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. V. Heymach, J. Desai, J. Manola, D. W. Davis, D. J. McConkey, D. Harmon, D. P. Ryan, G. Goss, T. Quigley, A. D. Van den Abbeele, et al.
Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas
Clin. Cancer Res., September 1, 2004; 10(17): 5732 - 5740.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Basu, C. Sarkar, D. Chakroborty, J. Nagy, R. B. Mitra, P. S. Dasgupta, and D. Mukhopadhyay
Ablation of Peripheral Dopaminergic Nerves Stimulates Malignant Tumor Growth by Inducing Vascular Permeability Factor/Vascular Endothelial Growth Factor-Mediated Angiogenesis
Cancer Res., August 15, 2004; 64(16): 5551 - 5555.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
N. Ferrara
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Endocr. Rev., August 1, 2004; 25(4): 581 - 611.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. L. Rakhmilevich, A. T. Hooper, D. J. Hicklin, and P. M. Sondel
Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody
Mol. Cancer Ther., August 1, 2004; 3(8): 969 - 976.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Chakroborty, C. Sarkar, R. B. Mitra, S. Banerjee, P. S. Dasgupta, and S. Basu
Depleted Dopamine in Gastric Cancer Tissues: Dopamine Treatment Retards Growth of Gastric Cancer by Inhibiting Angiogenesis
Clin. Cancer Res., July 1, 2004; 10(13): 4349 - 4356.
[Abstract]